Literature DB >> 32036583

Mental health conditions and the risk of chronic opioid therapy among patients with rheumatoid arthritis: a retrospective veterans affairs cohort study.

Justin S Liberman1,2, Lucy D'Agostino McGowan3, Robert A Greevy4,5, James A Morrow6, Marie R Griffin4,6,7, Christianne L Roumie4,7, Carlos G Grijalva4,6.   

Abstract

OBJECTIVE: Patients with rheumatoid arthritis (RA) often receive opioid analgesics for pain management. We examined the association between mental health conditions and the risk of chronic opioid therapy.
METHODS: A retrospective cohort of veterans with RA initiating opioid use was assembled using Veterans Health Administration databases (2001-2012). Mental health conditions included anxiety (N = 1108, 12.9%), depression (N = 1912, 22.2%), bipolar disease (N = 131, 1.5%), and post-traumatic stress disorder (N = 768, 8.9%) and were identified by ICD coded diagnoses and use of specific medications. Cohort members were followed from opioid initiation through chronic opioid therapy, defined as the continuous availability of opioids for at least 90 days. Multivariable Cox proportional hazard regression models assessed the association between mental health conditions and chronic opioid therapy accounting for relevant covariates. Subgroup analyses examined whether the strength of the observed association varied by the duration of the initial opioid prescription.
RESULTS: We identified 14,767 patients with RA with 22,452 episodes of opioid use initiation. Mental health conditions were identified in 8607 (38.3%) patients. Compared with patients without mental health conditions, patients with mental health conditions have a higher risk of developing chronic opioid therapy (469.3 vs 378.1 per 1000 person-years, adjusted hazard ratio [aHR] 1.18, 95% CI 1.09, 1.29). The increased risk was highest for those with a history of opioid use disorder (aHR 1.94, 95% CI 1.09, 3.46) and also elevated for those with other substance use disorders (aHR 1.35, 95% CI 1.05, 1.73). Duration of the initial opioid prescription was independently associated with chronic opioid therapy, regardless of the estimated opioid daily dose.
CONCLUSIONS: History of mental health conditions and duration of the initial opioid prescription were associated with an increased risk of chronic opioid therapy among patients with RA.Key Points• Approximately a third of patients with RA are exposed to opioid analgesics.• Patients with RA and history of mental health disease, especially substance use disorders, who initiate opioid use have an increased risk of chronic opioid therapy.• This study provides insight in an underrepresented population of mainly male patients with RA.

Entities:  

Keywords:  DMARDs; Mental health; Opioid analgesics; Rheumatoid arthritis

Mesh:

Substances:

Year:  2020        PMID: 32036583      PMCID: PMC7337604          DOI: 10.1007/s10067-020-04955-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

1.  Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective.

Authors:  Laxmaiah Manchikanti; Bert Fellows; Hary Ailinani; Vidyasagar Pampati
Journal:  Pain Physician       Date:  2010 Sep-Oct       Impact factor: 4.965

2.  Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.

Authors:  Andrew D Wiese; Marie R Griffin; C Michael Stein; Edward F Mitchel; Carlos G Grijalva
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

3.  Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States.

Authors:  Jeffrey R Curtis; Fenglong Xie; Christian Smith; Kenneth G Saag; Lang Chen; Timothy Beukelman; Melissa Mannion; Huifeng Yun; Stefan Kertesz
Journal:  Arthritis Rheumatol       Date:  2017-08-13       Impact factor: 10.995

4.  Effect of Preoperative Opioid Exposure on Healthcare Utilization and Expenditures Following Elective Abdominal Surgery.

Authors:  Jennifer F Waljee; David C Cron; Rena M Steiger; Lin Zhong; Michael J Englesbe; Chad M Brummett
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

5.  Opioid dose and drug-related mortality in patients with nonmalignant pain.

Authors:  Tara Gomes; Muhammad M Mamdani; Irfan A Dhalla; J Michael Paterson; David N Juurlink
Journal:  Arch Intern Med       Date:  2011-04-11

6.  Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study.

Authors:  Andrew D Wiese; Marie R Griffin; William Schaffner; C Michael Stein; Robert A Greevy; Edward F Mitchel; Carlos G Grijalva
Journal:  Ann Intern Med       Date:  2018-02-13       Impact factor: 25.391

7.  Protein kinase C phosphorylates a component of NADPH oxidase of neutrophils.

Authors:  E Papini; M Grzeskowiak; P Bellavite; F Rossi
Journal:  FEBS Lett       Date:  1985-10-14       Impact factor: 4.124

Review 8.  A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain.

Authors:  Laxmaiah Manchikanti; Hary Ailinani; Dhanalakshmi Koyyalagunta; Sukdeb Datta; Vijay Singh; Ike Eriator; Nalini Sehgal; Rinoo Shah; Ramsin Benyamin; Ricardo Vallejo; Bert Fellows; Paul J Christo
Journal:  Pain Physician       Date:  2011 Mar-Apr       Impact factor: 4.965

9.  Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis.

Authors:  T Heiberg; A Finset; T Uhlig; T K Kvien
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

Review 10.  Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines.

Authors:  Andrea M Trescot; Standiford Helm; Hans Hansen; Ramsin Benyamin; Scott E Glaser; Rajive Adlaka; Samir Patel; Laxmaiah Manchikanti
Journal:  Pain Physician       Date:  2008-03       Impact factor: 4.965

View more
  1 in total

Review 1.  Review of publications evaluating opioid use in patients with inflammatory rheumatic disease.

Authors:  Christine Anastasiou; Jinoos Yazdany
Journal:  Curr Opin Rheumatol       Date:  2022-03-01       Impact factor: 5.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.